We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

News   Nov 30, 2005

 
Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement
 
 
 

RELATED ARTICLES

Drug Candidate Could Recover Vocal Abilities Lost to ADNP Syndrome

News

A new Tel Aviv University study finds that the drug candidate CP201, also known as NAP, may improve vocal communication abilities that are underdeveloped in Activity-dependent neuroprotective protein (ADNP) patients.

READ MORE

Molecular Mechanisms of Ancient Herbal Remedies

News

Analysis of leaf extract reveals novel chemistry for therapeutic ion channel activation.

READ MORE

Reflecting on Norovirus Outbreaks May Help Guide Vaccine Development

News

Study confirms several factors that can make norovirus outbreaks more severe and may help guide efforts to develop a vaccine to prevent this highly contagious disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE